Back

Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in ATRT

Merk, D. J.; Hirsch, S.; Tsiami, F.; Walter, B.; Haeusser, L. A.; Babaei, S.; Admar, J.; Casadei, N.; Roggia, C.; Spohn, M.; Schittenhelm, J.; Singer, S.; Schueller, U.; Piccioni, F.; Persky, N. S.; Root, D. E.; Claassen, M.; Tatagiba, M.; Tabatabai, G.

2020-12-09 cancer biology
10.1101/2020.12.09.417378 bioRxiv
Show abstract

Atypical teratoid rhabdoid tumors (ATRT) are incurable high-grade pediatric brain tumors. Concepts for molecular-driven therapies in ATRTs lag behind, mainly due to the absence of actionable genetic alterations. We performed genome-wide CRISPR/Cas9 knockout screens in six human ATRT cell lines and identified a total of 671 context-specific essential genes. Based on these genetic dependencies, we constructed a library of small-molecule inhibitors that we found to preferentially inhibit growth of ATRT cells. CDK4/6 inhibitors, among the most potent drugs in our library, are capable of inhibiting tumor growth due to mutual exclusive dependency of ATRTs on CDK4 or CDK6. These distinct dependencies drive heterogeneity in response to CDK4/6 inhibitors in ATRTs. Our approach might serve as a blueprint for fostering the identification of functionally-instructed therapeutic strategies in other incurable diseases beyond ATRT, whose genomic profiles also lack actionable alterations so far.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.